{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Percent of participants with distant metastasis-free survival","groups":[{"description":"docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG000","title":"Oral Erlotinib Hydrochloride"}],"paramType":"NUMBER","populationDescription":"Participants enrolled in study","reportingStatus":"POSTED","timeFrame":"At 3 years","title":"Percent of Participants With Distant Metastasis-free Survival","type":"SECONDARY","unitOfMeasure":"percent"}